Evidence map›Paper›PMID 25849793›Full record

ArticlePloS one2015

Probing ADAMTS13 substrate specificity using phage display.

Karl C Desch, Colin Kretz, Andrew Yee, Robert Gildersleeve, Kristin Metzger, Nidhi Agrawal, Jane Cheng, David Ginsburg

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.1field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 13 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. ADAMTS-13 and von Willebrand factor: a dynamic duo.Journal of thrombosis and haemostasis : JTH · 2018
    Review
  6. Article
  7. Conformational quiescence of ADAMTS-13 prevents proteolytic promiscuity.Journal of thrombosis and haemostasis : JTH · 2016
    Article
  8. Massively parallel enzyme kinetics reveals the substrate recognition landscape of the metalloprotease ADAMTS13.Proceedings of the National Academy of Sciences of the United States of America · 2015
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Karl C DeschDepartment of Pediatrics, University of Michigan, Ann Arbor, Michigan, United States of America.
Colin KretzLife Sciences Institute, University of Michigan, Ann Arbor, Michigan, United States of America.
Andrew YeeLife Sciences Institute, University of Michigan, Ann Arbor, Michigan, United States of America.
Robert GildersleeveLife Sciences Institute, University of Michigan, Ann Arbor, Michigan, United States of America.
Kristin MetzgerLife Sciences Institute, University of Michigan, Ann Arbor, Michigan, United States of America.
Nidhi AgrawalLife Sciences Institute, University of Michigan, Ann Arbor, Michigan, United States of America.
Jane ChengLife Sciences Institute, University of Michigan, Ann Arbor, Michigan, United States of America.
David GinsburgHoward Hughes Medical Institute, Ann Arbor, Michigan, United States of America; Department of Internal Medicine and Human Genetics, University of Michigan, Ann Arbor, Michigan, United States of America.
University of Michigan–Ann Arbor · USMichigan United · US

Funding

TRANSGENIC MODELS FOR THE STUDY OF FACTOR V FUNCTIONP01HL057346 · NHLBI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI KAUFMAN, RANDAL J. · 1997 to 2013
$19.9M
Molecular Genetic Study of von Willebrand FactorR01HL039693 · NHLBI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI GINSBURG, DAVID · 1989 to 2016
$2.4M
Howard Hughes Medical InstituteNHLBI NIH HHS P01 HL057346NHLBI NIH HHS R01 HL039693
6 · The paper itself

Abstract

Von Willebrand factor (VWF) is a large, multimeric protein that regulates hemostasis by tethering platelets to the subendothelial matrix at sites of vascular damage. The procoagulant activity of plasma VWF correlates with the length of VWF multimers, which is proteolytically controlled by the metalloprotease ADAMTS13. To probe ADAMTS13 substrate specificity, we created phage display libraries containing randomly mutated residues of a minimal ADAMTS13 substrate fragment of VWF, termed VWF73. The libraries were screened for phage particles displaying VWF73 mutant peptides that were resistant to proteolysis by ADAMTS13. These peptides exhibited the greatest mutation frequency near the ADAMTS13 scissile residues. Kinetic assays using mutant and wild-type substrates demonstrated excellent agreement between rates of cleavage for mutant phage particles and the corresponding mutant peptides. Cleavage resistance of selected mutations was tested in vivo using hydrodynamic injection of corresponding full-length expression plasmids into VWF-deficient mice. These studies confirmed the resistance to cleavage resulting from select amino acid substitutions and uncovered evidence of alternate cleavage sites and recognition by other proteases in the circulation of ADAMTS13 deficient mice. Taken together, these studies demonstrate the key role of specific amino acids residues including P3-P2' and P11', for substrate specificity and emphasize the importance in flowing blood of other ADAMTS13-VWF exosite interactions outside of VWF73.

Indexed as

Peptide LibraryADAM ProteinsADAMTS13 ProteinAmino Acid SequenceAnimalsHEK293 CellsHumansMetalloendopeptidasesMiceMolecular Sequence DataMutationProteolysisSubstrate Specificityvon Willebrand FactorADAM ProteinsADAMTS13 ProteinADAMTS13 protein, humanADAMTS13 protein, mouseMetalloendopeptidasesPeptide Libraryvon Willebrand Factor

Identifiers

PMID25849793
PMCPMC4388381
OpenAlexW2003097747

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.